Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study was to evaluate the protective effect of dexmedetomidine on myocardial injury during liver transplantation
Liver transplantation surgery may lead to myocardial injury. Dexmedetomidine, a highly specific α2-adrenoeptor agonist, has sedative and analgesic properties without significant respiratory depression at the clinically approved dosage. Some investigations indicated that dexmedetomidine was able to protect the myocardium via improving the activity of Na+-K+-adenosine triphosphate enzyme and Ca2+-adenosine triphosphate, alleviating inflammation reaction and avoiding Ca2+ overload. However, the effect and the mechanism of dexmedetomidine on myocardial injury during liver transplantation remain unclear.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Dexmedetomidine Group | Experimental | Dexmedetomidine infusion:loading 0.5ug/kg for 10min, then 0.5 ug/kg/h until the end of operation. |
|
| Normal saline Group | Placebo Comparator | Equal volume normal saline substitute for dexmedetomidine |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Dexmedetomidine | Drug | Dexmedetomidine infusion:loading 0.5ug/kg for 10min, then 0.5 ug/kg/h until the end of operation. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Peri-operative mortality | through study completion, an average of 5 weeks | |
| The incidence of cardiac complications | from anesthesia induction to 24 hours after operation |
| Measure | Description | Time Frame |
|---|---|---|
| Evidences of Clinically Definite Myocardial Injury Confirmed by Electrochemiluminescence | myohemoglobin,creatine kinase isoenzyme,cardiac troponinâ… ,Heart-type fatty acid-binding protein | before skin incision, 0.5 hour min after anhepatic, 2 hours of neohepatic stage,the end of surgery,24 hours after operation |
| Measure | Description | Time Frame |
|---|---|---|
| Length of ICU stay | through study completion, an average of 5 days | |
| length of stay | from date of admission to discharge time | through study completion, an average of 6 weeks |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Wenli Yu, PhD | Contact | 86-13920098326 | yzxyuwenli@163.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| No.24 Fukang Road,Nankai District | Recruiting | Tianjin | Tianjin Municipality | 300192 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D020927 | Dexmedetomidine |
| D000077330 | Saline Solution |
| ID | Term |
|---|---|
| D007093 | Imidazoles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Normal saline | Drug | Equal volume normal saline substitute for dexmedetomidine |
|
| D000077324 |
| Crystalloid Solutions |
| D007552 | Isotonic Solutions |
| D012996 | Solutions |
| D004364 | Pharmaceutical Preparations |